Serum Paraoxonase-1 Activity in Prostate Cancer Patients Treated with Brachytherapy as a Measure of Irradiation Efficacy

Dorota Olszewska-Słonina; Miłosz Jasiński

doi:10.3390/antiox12020212

Serum Paraoxonase-1 Activity in Prostate Cancer Patients Treated with Brachytherapy as a Measure of Irradiation Efficacy

Antioxidants (Basel). 2023 Jan 17;12(2):212. doi: 10.3390/antiox12020212.

Authors

Dorota Olszewska-Słonina¹, Miłosz Jasiński²

Affiliations

¹ Department of Pathobiochemistry and Clinical Chemistry, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toruń, Poland.
² Department of Urology and Urological Oncology, Collegium Medicum, University of Zielona Góra, 65-417 Zielona Góra, Poland.

Abstract

We investigated changes in the activity of antioxidant paraoxonase-1 (PON1) in patients with prostate cancer (PCa) undergoing radiotherapy (RT), as well as the relationship of the PON1 activity with the degree of PCa advancement. We included 84 men with PCa. Blood samples were obtained before irradiation and after the completion of RT. The control group was composed of 60 healthy men. There was no significant difference in the PON1 activity between the control group and patients pre-radiotherapy. Irradiation was associated with a significant decrease in the PON1 activity; thus, it could be a measure of the efficacy of RT. No significant correlations between the PON1 activity and Gleason score, prostate volume, BMI (body mass index), or adipose tissue thickness were found. However, there was a positive correlation between the PON1 activity and the PSA concentration in the group of PCa patients.

Keywords: paraoxonase-1; prostate cancer; radiotherapy.

Grants and funding

This research received no external funding.